Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male participants and their partners of child-bearing potential must be willing to use two effective contraceptive methods~* Female participants must be either postmenopausal or surgically sterile~* Intact normal skin in the area for intended injection~* Body weight less than (\<) 150 kilograms (kg)~* Have no contraindications from the following: a detailed medical and surgical history, a complete physical examination, including vital signs, 12-lead electro cardio gram (ECG), hematology, blood chemistry, serology, and urinalysis~Exclusion Criteria:~* Participants with any known active current or history of recurrent Infectious disease~* Positive result on hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus-1 (HIV-1) and HIV-2 at screening~* A history of clinically significant gastrointestinal, renal, hepatic, cardiovascular, or allergic disease~* Evidence of malignant disease, or malignancies diagnosed within the previous 5 years~* Use of or being dependent within the last 12 months on any substances of abuse, including a relevant past history of alcohol abuse~* Participants with a history of, or currently active primary or secondary immunodeficiency~* Participants who smoke more than 10 cigarettes per day or equivalent in tobacco~* Clinically relevant deviation from normal in the physical examination, including vital signs~* Clinically relevant ECG abnormalities on screening~* Evidence of atrial fibrillation, atrial flutter, right or left bundle branch block, Wolf-Parkinson-White syndrome, or cardiac pacemaker or any other significant cardiac abnormalities~* Known allergy to TCZ or any other ingredient in the subcutaneous (SC) formulation~* History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies~* Known coagulopathy~* Clinically significant abnormalities in laboratory test results~* Immunization with a live or attenuated vaccine is prohibited within 4 weeks prior to study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- A1: Tocilizumab AI followed by PFS-NSD in abdomen (Type: EXPERIMENTAL): Participants will receive two single doses of 162 milligrams (mg) tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in abdomen.
- A2: Tocilizumab AI followed by PFS-NSD in thigh (Type: EXPERIMENTAL): Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2) in thigh.
- A3: Tocilizumab AI followed by PFS-NSD in upper arm (Type: EXPERIMENTAL): Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in upper arm.
- B1: Tocilizumab PFS-NSD followed by AI in abdomen (Type: EXPERIMENTAL): Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in abdomen.
- B2: Tocilizumab PFS-NSD followed by AI in thigh (Type: EXPERIMENTAL): Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
- B3: Tocilizumab PFS-NSD followed by AI in upper arm (Type: EXPERIMENTAL): Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.

Based on this trial design, predict the completion outcome and termination type (if applicable).